From Wikipedia, the free encyclopedia
- crizotinib (Xalkori) and ceritinib (Zykadia), approved by the FDA for treatment of NSCLC.
- Alectinib (Alecensa) (Chugai, NDA has been filed in Japan) (breakthrough status in U.S.) FDA approved Dec 2015.
||This section needs to be updated. (February 2016)|
Additional ALK inhibitors currently (or soon to be) undergoing clinical trials include:
- Dalantercept, ACE-041 (Acceleron)
- Brigatinib (AP26113) (by Ariad) (breakthrough status in U.S.) (also an EGFR inhibitor)
- Entrectinib (Nerviano's NMS-E628, licensed by Ignyta and renamed RXDX-101, in the U.S. orphan drug designation and rare pediatric disease designation for the treatment of neuroblastoma and orphan drug designation for treatment of TrkA-, TrkB-, TrkC-, ROS1- and ALK-positive NSCLC)
- PF-06463922 (Pfizer)
- TSR-011 (Tesaro)
- CEP-37440 (Teva)
- X-396 (Xcovery)
Updates for several of these will be available at the start of June at ASCO 2014.
- Nelsen (2010). "ALK Inhibitors: Possible New Treatment for Lung Cancer".
- Farmer (2010). "Non-Small-Cell Lung Cancer Standards of Care Challenged by a Cornucopia of New Drugs".
- Chustecka (2010). "Crizotinib in ALK-NSCLC; Response Rate "Unprecedented"".
- "FDA Approves Ceritinib for ALK-Positive Lung Cancer". Medscape. April 29, 2014.
- "Dalantercept". AdisInsight. Retrieved 15 February 2017.
- Galkin; et al. (2007). "Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK".
- "Archived copy". Archived from the original on 2010-12-23. Retrieved 2010-10-02.